Threshold Pharmaceuticals, Inc.  

(Public, NASDAQ:THLD)   Watch this stock  
Find more results for Robert L. Tillman
4.17
-0.01 (-0.24%)
Jul 24 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 4.14 - 4.25
52 week 3.51 - 5.93
Open 4.20
Vol / Avg. 198,082.00/382,049.00
Mkt cap 247.47M
P/E     -
Div/yield     -
EPS -0.55
Shares 59.35M
Beta 2.28
Inst. own 70%
Jul 28, 2014
Q2 2014 THRESHOLD PHARMACEUTICALS INC Earnings Release (Estimated) Add to calendar
Jul 8, 2014
Threshold Pharmaceuticals Inc at Piper Jaffray Catalyst Symposium
Jun 5, 2014
THRESHOLD PHARMACEUTICALS INC at Jefferies Global Healthcare Conference
Jun 1, 2014
THRESHOLD PHARMACEUTICALS INC Analyst Meeting at the 50th Annual Meeting of the American Society of Clinical Oncology (ASCO)
May 20, 2014
THRESHOLD PHARMACEUTICALS INC at UBS Global Healthcare Conference
May 16, 2014
THRESHOLD PHARMACEUTICALS INC Annual Shareholder Meeting
May 1, 2014
Q1 2014 THRESHOLD PHARMACEUTICALS INC Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q1 (Mar '14) 2013
Net profit margin -193.13% -227.41%
Operating margin -233.80% -208.28%
EBITD margin - -196.22%
Return on average assets -28.69% -29.35%
Return on average equity - -
Employees 53 -
CDP Score - -

Address

Suite 300, 170 Harbor Way
SOUTH SAN FRANCISCO, CA 94080
United States - Map
+1-650-4748200 (Phone)
+1-650-4742529 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Threshold Pharmaceuticals, Inc. is a biotechnology company focused on the discovery and development of drugs targeting the microenvironment of solid tumors and the bone marrows of some hematologic malignancies (blood cancers) as treatments for patients living with cancer. The Company's hypoxia activated prodrug product candidates, including TH-302, are designed to specifically target the hypoxic microenvironment of tumors by selective activation of the prodrug to release a potent cytotoxin. The Company's focus is on product candidates for the treatment of patients with cancer. The Company's clinical development efforts are focused on TH-302, for which the Company entered a license and co-development agreement with Merck KGaA, on February 2, 2012, for worldwide development and commercialization. As of December 31, 2011, TH-302 is in Phase I, Phase II and Phase III clinical trials. The Company reported updated results from the Phase I monotherapy trial of TH-302.

Officers and directors

Harold E. Selick Ph.D. Chief Executive Officer, Director
Age: 59
Bio & Compensation  - Reuters
Robert L. Simon Senior Vice President - Regulatory Affairs and Quality Assurance
Age: 79
Bio & Compensation  - Reuters
Joel A. Fernandes Vice President - Finance, Controller
Age: 44
Bio & Compensation  - Reuters
Nipun Davar Ph.D. Vice President - Pharmaceutical Development and Manufacturing
Age: 46
Bio & Compensation  - Reuters
Tillman Pearce M.D. Chief Medical Officer
Age: 57
Bio & Compensation  - Reuters
Jeffrey W. Bird M.D., Ph.D. Independent Director
Age: 53
Bio & Compensation  - Reuters
Bruce C. Cozadd Independent Director
Age: 50
Bio & Compensation  - Reuters
David R. Hoffmann Independent Director
Age: 69
Bio & Compensation  - Reuters
Wilfred E. Jaeger M.D. Independent Director
Age: 58
Bio & Compensation  - Reuters
George G. C. Parker Ph.D. Independent Director
Age: 75
Bio & Compensation  - Reuters